0,1,2,3,4,5
Table 28: Summary of clinical evidence of PTT as monotherapy,,,,,
Author/year,Study type,Device,No. of   patients,Hours of use,Result
Levine et al. (2008),"Pilot   Prospective,   uncontrolled",Fast Size®,10,2-8h  6 months,Mean reduction in PC   33% (51º-34º)   SPL: + 0.5-2 cm   EG: + 0.5-1 cm   IIEF: + 5.3
Gontero et al.   (2009),Phase II   Prospective   Uncontrolled,Andropenis®,15,> 5h   6 months,Mean reduction in PC:   N/S   SPL: + 0.8 cm (6 mo)   + 1.0 cm (12 mo)
Martinez-  Salamanca et al.   (2014),"Prospective,   controlled, open   label   Men in AP",Andropenis®,96   55 (PD)   41 (NIG),6-9h (4.6 h/d)   6 months,Mean reduction in PC:   20º (33º-15º) p < 0.05.   SPL: + 1.5 cm (6 mo)   EG: + 0.9 cm (6 mo)
Moncada el al.   (2018),Controlled   multicenter trial   Men in CP,Penimaster®PRO,80   41 (PTT)   39 (NIG),3-8h   3 months,Mean reduction in PC:   31º (50º-15º).   SPL: + 1.8 cm (3 mo)   EG: + 0.9 cm (6 mo)   IEEF: + 2.5
Ziegelmann et al.   (2019) [1142],"Randomised,   prospective,   controlled, single   blind study   Men in CP and   contols 3:1",Restorex®,110,30-90 min/day   3 months,Mean reduction in PC   (3 mo): 13.3º (PTT)   + 1.3º (control)    p < 0.001   SPL: + 1.5 cm (PTT) +   0 cm (control)    p < 0.001   IIEF: + 4.3 (PTT) -0.7   (control) p = 0.01
